Association between the TP53 and CYP2E1*5B gene polymorphisms and non-small cell lung cancer

  • Ahmet Oguz Ada Department of Toxicology, Faculty of Pharmacy, University of Ankara, Tandogan, Ankara
  • Serdar Bilgen Department of Toxicology, Faculty of Pharmacy, University of Ankara, Tandogan, Ankara
  • Volkan Karacaoglan Department of Toxicology, Faculty of Pharmacy, University of Ankara, Tandogan, Ankara
  • Celalettin Semih Kunak Department of Toxicology, Faculty of Pharmacy, University of Ankara, Tandogan, Ankara
  • Emre Soydas Department of Toxicology, Faculty of Pharmacy, University of Ankara, Tandogan, Ankara
  • Sibel Alpar Ataturk Pulmonary Diseases and Thoracic Surgery Hospital, Sanatoryum, Ankara
  • Meral Gulhan Ataturk Pulmonary Diseases and Thoracic Surgery Hospital, Sanatoryum, Ankara
  • Mumtaz Iscan Department of Toxicology, Faculty of Pharmacy, University of Ankara, Tandogan, Ankara
Keywords: carcinogen metabolism, CYP2E1, genetic polymorphism, GST, NSCLC

Abstract

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer. Genetic polymorphisms in tumour suppressor genes and genes encoding xenobiotic metabolising enzymes alter the activity of their corresponding enzymes and are important individual susceptibility factors for NSCLC. Because of the lack of information in literature, the aim of our study was to investigate the role of the tumour suppressor gene TP53 (Arg72Pro) and the xenobiotic metabolising CYP2E1*5B gene polymorphisms on the risk of NSCLC development. The study population consisted of 172 patients and 172 controls (156 men and 16 women in each group). Genetic polymorphisms were determined with real-time polymerase chain reaction (PCR) and PCR restriction fragment length polymorphism (PCR-RFLP). Multivariate analysis showed a significant association with NSCLC for the combination between the TP53 codon72 Arg/Pro and the Pro/Pro genotypes (OR 2.21, 95 % CI 1.39–3.51; p=0.001). We also analysed whether combinations of these gene variants with GSTM1, GSTT1, GSTP1 exon 5 (Ile105Val), and GSTP1 exon 6 (Ala114Val) gene polymorphisms were associated with the NSCLC risk. A significant increase in the risk was observed for the following combinations: TP53 codon72 variant with GSTM1 null (OR 2.22, 95 % CI 1.23-4.04; p=0.009), GSTT1 null (OR 2.98, 95 % CI 1.49-5.94; p=0.002), and GSTP1 (Ala114Val) variant genotypes (OR 3.38, 95 % CI 1.54-7.41; p=0.002). Further studies with larger samples are needed to verify these findings.
Published
2016-12-15
How to Cite
1.
Ada A, Bilgen S, Karacaoglan V, Kunak C, Soydas E, Alpar S, Gulhan M, Iscan M. Association between the TP53 and CYP2E1*5B gene polymorphisms and non-small cell lung cancer. AIHT [Internet]. 15Dec.2016 [cited 19Jul.2019];67(4). Available from: https://arhiv.imi.hr/index.php/arhiv/article/view/558
Section
Original article